Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 10, 2026

ING rolls out global subscription banking model

View original at globenewswire.com
ING rolls out global subscription banking model ING rolls out global subscription banking model ING today announced a new global subscriptions model designed to make daily banking easier and deliver greater value for customers…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Customers want everyday banking to be simpler, designed around their lifestyle and with more flexibility, based on extensive customer research

    60% confidence

  • There are already 3 million customers enjoying the benefits of the new subscription plans, including customers migrated from existing offerings

    60% confidence

  • MSCI upgraded ING's ESG rating from 'AA' to 'AAA' in October 2025

    60% confidence

  • ING is already seeing strong early interest from customers in the markets where the subscription model has launched

    60% confidence

  • ING's management of ESG material risk is 'Strong' with an ESG risk rating of 18.0 (low risk)

    60% confidence

  • The subscription model move marks an important step in ING's strategy to evolve from product-based banking towards more relationship-based customer propositions

    60% confidence

  • ING sees a real opportunity to create value for customers and acted on growing customer demand for simplicity, transparency and lifestyle-aligned benefits

    60% confidence

  • ING's customer research shows a growing demand for simplicity, transparency, and benefits that fit everyday life

    60% confidence

Data points we hold from this source

ING Group · cash600 USD
ING Group · market share41 millions_customers
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com